Published in

Springer Science and Business Media LLC, 2018

DOI: 10.17863/cam.30334

Nature Research, Nature Communications, 1(7), 2016

DOI: 10.1038/ncomms12342

Links

Tools

Export citation

Search in Google Scholar

A protein truncating R179X variant in RNF186 confers protection against ulcerative colitis

Journal article published in 2015 by K. de Lange, K. de Lane, Manuel A. Rivas, Daniel Graham, Taru Tukianen, Patrick Sulem ORCID, A. Nicole Desch, Christine Stevens, Philippe Goyette, A. Nicole Desch, Rivas Ma, Daniel Gudbjartsson ORCID, Ingileif Jonsdottir, Mitja I. Kurki, Severine Vermeire and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Question mark in circle
Preprint: policy unknown
Upload
Question mark in circle
Postprint: policy unknown
Upload
Question mark in circle
Published version: policy unknown
Upload

Abstract

AbstractProtein-truncating variants protective against human disease provide in vivo validation of therapeutic targets. Here we used targeted sequencing to conduct a search for protein-truncating variants conferring protection against inflammatory bowel disease exploiting knowledge of common variants associated with the same disease. Through replication genotyping and imputation we found that a predicted protein-truncating variant (rs36095412, p.R179X, genotyped in 11,148 ulcerative colitis patients and 295,446 controls, MAF=up to 0.78%) in RNF186, a single-exon ring finger E3 ligase with strong colonic expression, protects against ulcerative colitis (overall P=6.89 × 10−7, odds ratio=0.30). We further demonstrate that the truncated protein exhibits reduced expression and altered subcellular localization, suggesting the protective mechanism may reside in the loss of an interaction or function via mislocalization and/or loss of an essential transmembrane domain.